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quences but also an economic impact. In this article, using a theoretical
model, we evaluate four medication administration systems: conven-
tional preparation by nursing staff, MINIBAG Plus delivery system,
compounding center preparation, and premix drugs. Methods: We
designed a decision tree model from a third-party payer perspective,
and the time horizon of the acute event. Local costs, in Colombian pesos
(US $1¼ 1784 COP$), were obtained from tariff manuals, medication costs
from Sismed information system, and clinical variables from the pub-
lished literature, and uncertainty was dealt with by an expert panel. The
drug used for the model was dopamine. Results: Average costs for eachee front matter Copyright & 2014, International S
r Inc.
1016/j.vhri.2014.05.001
st: This study was supported by an unrestricted
selli@gmail.com.
ondence to: Diego Rosselli, Faculty of Medicine,
na, Carrera 7 No. 40-62, Piso 2 Hospital San Ignacdopamine dose delivered were $46,995 for premix, $47,625 for com-
pounding center, $101,934 for MINIBAG Plus, and $108,870 for drug
prepared in the ICU. The variability of these results is higher for
compounding center than for premix, and even higher for MINIBAG Plus
and nurse delivery. Conclusions: The use of premix drugs can be a cost-
saving strategy, which decreases medical errors in drug administration in
the ICU, particularly if it is part of an integral error reduction program.
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The aphorism primum non nocere—above all, do no harm—
included in the Hippocratic Oath has regained particular rele-
vance 2500 years later. In health care systems worldwide,
effectiveness, as the ﬁnal goal for therapeutic interventions, has
been placed in a balance in which safety and cost also play
primary roles [1]. Much has been written on medical error (a
mistake by any health care team member, not only physicians)
since the controversial book To Err Is Human was published [2],
which showed how errors could lead to 1 million injuries and
about 100,000 deaths per year in the United States alone.
Nowhere else is the “error” issue as sensitive as in the
intensive care unit (ICU) [3]. The combination of high complexity,
interventional diversity, and critically ill patients make the ICU
particularly vulnerable to medical errors [4]. A multinational trial
that included 205 ICUs showed 38.8 “incidents” per 100 patient-
days in ﬁve domains: intravenous (IV) lines and accesses, airway
management, equipment, alarms, and medications [5]. It is
estimated that 1 of every 10 IV infusions at the ICUs are either
erroneously prepared or administered [3]. When only medication
errors are considered, the estimation is 10.5 incidents per 100
patient-days in the prescription and administration stages [5].Error prevalence at ICUs is uncertain; estimation of the frequency
of errors during drug administration ranges between 1.2 and 947 per
1000 patient-days in adults [3]. Such range results from medical
error reporting mechanisms; for example, in independently reported
trials, the prevalence is lower. An example is the study by Taxis and
Barber [6] in which 1328 patients from 113 ICUs in 27 countries were
included, with Brazil and Argentina as the only Latin American
representatives. Types of errors evaluated were omissions, wrong
drug, wrong dose, wrong administration route, and improper dosing
time. The estimated prevalence in this study was 74.5 errors per
every 100 patient-days; interestingly, 19% of the participating ICUs
reported no errors during the study period.
The incidence of errors with injectable medications is higher than
with other forms of medications [7]. Of the ﬁve stages in IV
medication administration (prescription, transcription, dispensation,
administration, and monitoring), the drug administration phase is
most prone to errors [8], which can be further classiﬁed as follows:
omission, inadequate dosing, inadequate concentration, wrong med-
ication, incorrect technique, incorrect administration route, improper
administration rate, incorrect dosing time, and wrong patient. Con-
sequences of these errors are also classiﬁed, in increasing severity,
with a lettered-scale that ranges from B to I, with B corresponding to a
wrong medication that is not administered and I to an error thatociety for Pharmacoeconomics and Outcomes Research (ISPOR).
grant from Baxter Colombia.
Clinical Epidemiology and Biostatistics Department, Pontiﬁcia
io, Bogotá, Colombia.
Table 1 – Classiﬁcation of medical errors by Calabrese et al. [9], as per error type clustering used by the authors
and the corresponding incidence probability (once an error has occurred).
Category Deﬁnition Error type Probability (%) Reference
A Quasi error
No harm 92 [10]B Wrong drug, not administered
C Medication administered without consequences
D Monitoring required but no symptoms Mild harm 6.33 [10]
E Symptoms development, management required
Moderate harm 1.44 [6]F Hospital stay is required or increased
G Permanent consequences develop
Severe harm 0.42 [6]H Risk of death (anaphylaxis, cardiac arrest)
I Death Death 0.21 [6]
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cation error is, therefore, quite variable. Most errors lead to either
minor harm or no harm at all, while it has been estimated that about
2% of the errors cause signiﬁcant injuries to patients [9].
Calabrese et al. [9] proposed another error classiﬁcation consid-
ering both drug administration route (e.g., subcutaneous adminis-
tration, IV bolus, and IV infusion) and drug class (e.g., antibiotics,
sedatives, vasopressors, and insulin). Despite the fact that no other
potential medication errors (microbiological contamination, com-
pounding errors such as wrong dilutant or drug concentration
miscalculation) were considered in this trial, error rate exceeded
the one reported in the previously described study as it reached 74.5
errors per 100 patient-days. Overall, an error occurs in about 7% of
all parenteral drug administrations [10]. Medication dosing errors
(118 of 861 recorded errors) had the most serious consequences as
they resulted in permanent harm in three patients and in the death
of other three patients. Other studies [3,11] report even higher error
rates regarding medication administration at the ICUs, reaching up
to 1 daily error per patient, on average [12].
Apart from having severe consequences on the patients’
health, errors have serious ﬁnancial consequences [13]. In a
sample of ICU patients in Switzerland (n ¼ 333), Nuckols et al.
[14] showed preventable IV drug administration–related adverse
events in 94 patients (28%). Such adverse events were associated
with an extended hospital stay (mean 4.8 days) as well as with
increased costs (mean US $4500) versus the control group.
The objective of this study was to develop an economic
evaluation model to estimate the costs and outcome impact of
four different IV drug administration systems (assuming the
same drug) at the ICU setting in Colombia.Fig. 1 – Decision tree outline. Errors include preparation-
related, contamination, and biological risk errors. ICU,
intensive care unit.Methods
We designed a decision tree–type economic model using TreeAge
Pro Healthcare 2009 (Fig. 1). Four alternatives for IV drug delivery
were considered: use of premix drugs, compounding center
preparation, bedside preparation at the ICU by a nurse (but using
a buretrol set), and MINIBAG Plus use (ﬂexible closed system bag
with a vial adaptor—a point-of-care activated device). Baseline
data included in the model were extracted from international
medical journal publications (see Table 1) and subsequently
discussed and validated by an expert panel independently
selected by the investigators (with no sponsor participation).
The panel was composed of an internal medicine specialist, a
surgeon, two physicians specialized in pharmacology, and a
pharmacist. Dopamine was selected as the drug for the model
because it shows a larger cost difference between premix and
competitors. We used a third-party payer perspective (Colombian
health system), and the time horizon was the length of ICU stay
(which is similar to that reported in the literature); no discount
rate was applied because the period of analysis was shorter than1 year. Costs are in Colombian pesos (COP $) as for 2012 (as
reference, the exchange rate for July 2012 was US $1 ¼ COP $1784).
Model Assumptions
The main assumption of the model is that error incidence rates at
Colombian ICUs are similar to those published elsewhere. Calcu-
lations are based on a “typical” ICU adult patient.
Error risks
To estimate error risks, a literature review was carried out using
MeSH “Medication Errors,” “Drug Administration Schedule,”
“Drug Delivery Systems,” and “Intensive Care Units” as search
criteria. A total of 272 abstracts were reviewed; 27 articles were
selected for full-text review, of which 20 [4,5,9–11,13–27] reported
error rates. Among 113 ICUs from 27 countries, the only data from
the region came from Brazil [17] and from 6 ICUs (3 Argentinean
and 3 Brazilian) included in the study by Valentin et al. [5]. Error
probabilities used in the model (based on Nuckols et al. [14]), for
each individual drug administration, were as follows: 0.01 for
compounding center preparation (by pharmacists), 0.08 for bed-
side preparation by nursing staff, 0.03 for MINIBAG Plus, and
0.0027 for premix drugs. For our base-case scenario, we selected
the error rates of Taxis and Barber [6] and Klopotowska et al. [10]
because they were on the conservative side (we preferred to
underestimate the risk) and because they include a wide range of
error consequences. Only one reference [15] included error rates
for compounding centers versus premix medication. For the
sensitivity analysis, we arbitrarily assumed a wide range after
discussions with our expert panel. In error probabilities, we
considered it unpractical to convert rates to probabilities. We
used rates as probabilities because of the short time frame.
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Cost calculation for compounding center preparation
Initially, costs were obtained from a large compounding center
that prepares medications and parenteral nutrition solutions for
four high-complexity hospitals in Bogota. The microcosting
technique was used, in which administrative costs were distrib-
uted between oncology drugs, parenteral nutrition, antibiotics,
and other medications. Staff at this center includes 99 people, 78
of whom are pharmacists on different working schedules. Payroll
is almost COP $ 350 million, of which 30% corresponds to the
preparation of antibiotics and 52% to the preparation of other
drugs. On a monthly basis, 150,000 units are prepared (antibiotics
50,000, other drugs 95,000, remaining ones corresponding to
oncology drugs and parenteral nutrition). These data result in
an estimated unit value of COP $17,552 for chemotherapy, COP
$14,306 for total parenteral nutrition, COP $2,050 for antibiotics,
and COP $1,888 for other drugs, before applying a proﬁt margin;
because of economies of scale, this last cost was the one used for
the lower limit of our model. For estimation of costs, three
additional hospital mixing centers were studied, in which unit
preparation costs ranged between COP $3,938 and COP $14,306
through microcosting techniques (we used COP $4,923 and COP
$17,883 as margins for the sensitivity analysis, applying a 25%
proﬁt margin). This wide range of costs could be accounted for by
the proportion of resources allocated to the preparation of
oncology drugs and parenteral nutrition products (whose costs
and proﬁt margin are both higher) and the volume of prepared
medications. In the model, for the base case, we used an average
cost of COP $13,468 per drug prepared at the compounding center.
Cost calculation for nursing staff preparation of buretrol, and
for premix drugs
These costs include IV drug preparation time at the ICU. For this
estimation, a chronometer was used while preparing and admin-
istering a convenience sample of 130 drugs for IV application at a
university hospital ICU in Bogota. Prolonged dilution medications
and drugs with no premix equivalent were excluded (e.g., piper-
acillin/tazobactam). On average, hand washing took 35.7 18.5 sec-
onds, mouth cover and gloves use 1.9  4.5 seconds, drug
preparation 135.2  250.0 seconds, and drug administration 64.8
 35.2 seconds, for 382.7  513.2 seconds in total for each
administered drug. This time (slightly over 6 minutes) was the
time used for the nursing staff and buretrol base case. The
literature review showed similar ﬁndings at a cardiology ICU in
Houston, Texas (91.8 seconds for drug preparation, 59.8 seconds
for drug administration, total time 313 seconds) [27]. The cost was
calculated on the basis of a professional nurse salary of $12,495
per hour (market price).
For the premix arm, same times for hand washing and mouth
cover/gloves use were used. In this case, drug preparation time
was shorter (24.1  27.2 seconds) and took into account the time
corresponding to cart medication collection and bag labeling. As
for administration time, same nurse delivery base-case items were
considered, that is, time for reaching the patient’s bed, for
positioning of protection elements, and for administering the
drug. The total time required in this arm was 136.2  58.0 seconds.
Drug costs
For the base-case scenario, we selected dopamine for cost
calculations because this was the drug with the greatest price
difference between the normal preparation and the premixed.
We assumed that if there were any cost savings with premixed
dopamine, where premixed preparation was the most expensive
compared with regular drugs, any potential difference in favor of
premix would be even greater with other ICU medications.Dopamine cost was obtained from annual sales (March 2011-
March 2012) according to Sismed (an ofﬁcial source of medication
price and sales volume information). In total, 17,555 units were
sold during this 12-month period. Because the unit value and
market share of dopamine were both known, we estimated a
weighted mean cost of COP $2910. For premixed dopamine, we
used the unit cost supplied by the manufacturer (COP $17,930), as
well as for MINIBAG Plus delivery system (COP $4,800).Error costs
In 2011, Carey and Stefos [12] published in Health Economics an
article in which they calculated the frequency of a series of errors
and quantiﬁed their costs. On the basis of a population from the
US veterans database (n ¼ 71.349 patients at risk), the researchers
estimated the median costs of a medical care–associated infec-
tion (US $42,309–US $60,199), sepsis (US$25,891–US $30,515), and a
work accident (pinching or laceration) (US$ 5,059–US $9,448). The
cost for the latter was higher than the one reported by Rivard
et al. [28] in 2008 (US $3359).
Because costs in Colombia are signiﬁcantly lower [29], follow-
ing discussion with the experts we assumed that harmless errors
(which account for 91.6% of the errors) do not incur costs, minor
errors (6.3%) incur an additional cost of COP $50,000 each,
intermediate errors (those leading to extended hospital stay by
2.4 days, and accounting for 1.4% of the errors) incur costs of COP
$3.1 million, and serious errors (0.6%) incur costs of COP $3.56
million. Despite the literature review, error costs were ﬁnally
estimated by the expert panel, who believe that these costs are
much lower than those reported in the literature.Sensitivity analysis
We started with a tornado diagram to ﬁnd which variables are
critical for the model. Then, we performed univariate and
bivariate sensitivity analysis. Because of the uncertainty sur-
rounding many of the variables, wide ranges have been used
(Table 2). We also performed a probabilistic sensitivity analysis
using uniform distributions for all the variables except for error
costs and compounding center costs, for which we used a gamma
distribution (Table 3).Results
According to the model, mean costs of a single IV dopamine dose
administration at the ICU, including error costs, would be as
follows: COP $46,995 for the premix drug, COP $47,625 for the
compounding center preparation, COP $101,934 for the MINIBAG
Plus delivery system, and COP $108,870 for drug preparation by
an ICU nurse. Variation within these mean costs is higher for
compounding center preparation than for premix drugs, due to
the number of variables involved in the respective processes.
This also applies to MINIBAG and nursing staff preparation,
compared with premix drugs.
According to the model, the rate of errors that lead to harm
(expressed as the number of errors per 10,000 administered
medications) is 1 for premix drugs, 2 for compounding center
preparations, 4 for MINIBAG Plus, and 17 for nurse drug delivery
(which is equivalent to 1 harming error per every 600 adminis-
tered medications).
A similar calculation for deaths attributable to a drug admin-
istration error, per every 100,000 IV medications administered,
resulted in 6 deaths for premix drugs, 21 for compounding center
preparations, 42 for MINIBAG Plus, and 168 for nurse staff
preparation delivered with buretrol.
Table 2 – Selected variables used in the model, with wide intervals used for the sensitivity analysis.
Variable Base case ($) Low ($) High ($) Source
Compounding center preparation 13,468 4,923 22,013 Author’s estimation
Compounding center application 30,582 22,752 25,240 Author’s estimation
Bedside application by nursing staff 100,639 74,226 83,410 Author’s estimation
MINIBAG Plus application 92,894 68,496 76,190 Author’s estimation
Premix drugs application 28,885 21,614 23,183 Author’s estimation
Professional nurse salary (h) 12,495 9,375 15,620 Market prices
Cost of dopamine 5,392 2,500 15,000 Weighted mean of market price
Day in ICU 1,291,523 600,000 2,000,000 Costs of local ICU
Cost of mild error 50,000 25,000 100,000 Expert panel estimation
Cost of moderate error 3,100,000 1,500,000 6,000,000 Expert panel estimation
Cost of severe error 3,560,000 1,800,000 7,200,000 Expert panel estimation
ICU, intensive care unit.
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The tornado simulation (Fig. 2) showed which variables could
change the decision (using the ranges preestablished by the
authors). The variable with the greatest effect on total cost is
the nurse salary, affecting all the four alternatives, but not
modifying the ﬁnal decision. Critical variables were the costs of
medication (in this case dopamine), and of compounding center
preparation, as well as the probabilities of errors that could cause
harm, and the rate of error with premix medication.
We found in the one-way sensitivity analysis that if each
preparation in the compounding center costs more than $13,468,
premix would be cost saving. This cost is one of the variables
with higher uncertainty in our model, so each institution should
be careful when estimating this particular cost. The difference
between the premix cost and plain medication is also important.
The two-way sensitivity analysis of the cost of premix and plain
dopamine shows that up to a difference of $15,000 in prices, the
premix would still be cost saving. If we assume ranges from
$1,000 to $10,000 for plain dopamine and $18,000 to $20,000 for
premix dopamine, the premix will be cost saving 42% of the times
for the possible combinations. Another two-way sensitivity
analysis for the error probability of compounding center and
premix shows that costs favor one or the other in a very similar
rate. In an in-hospital compounding center, the probability of
error is higher, which would favor the premix alternative.Discussion
This report has certain limitations: First, it is mainly based on
foreign studies, error probabilities are not adjusted to medication
type, and local costs are approximate. Drug delivery times wereTable 3 – Probabilities are per error occurring in IV drug a
the sensitivity analysis.
Error B
Error probabilities for bedside preparation by nursing staff
Error probabilities for MINIBAG Plus
Rate of error compounding center
Rate of error premix
Probability of “mild” consequences error
Probability of “moderate” consequences error
Probability of “severe” consequences error
ICU, intensive care unit; IV, intravenous.measured at a single ICU; however, they were not very different
from what has been reported in the literature, except for the
article by Rivard et al. [28] who reported shorter times; this might
be because their study was undertaken at a cardiology ICU in
which fewer antibiotics are used; preparation times of these
drugs are lengthier.
Our per-error costs were lower than those reported in the
literature; according to Nuckols et al. [14], adverse events asso-
ciated with drug errors increased hospitalization costs by 53% (on
average, US $6,647 were added to the baseline costs of US $12,529)
and were related to a longer stay (4.8 days more). Mortality rate
attributable to errors is also probably underestimated in our
model. Rothschild et al. [13] in 1490 patient-days found 54 cases
of errors, which either led to death (n ¼ 2), imminent danger (n ¼ 5),
or “some” consequence (n ¼ 28) or prolonged the length of stay
(n ¼ 19). In the study by Thomas et al. [30], among 3691 incidents
resulting in harm, 13 (0.35%) led to the patient’s death, 40 (1.1%)
to serious harm, 327 (8.9%) to moderate harm, and 857 (23.2%) to
minor harm, while 2454 (66.5%) led to no harm at all. With these
data in mind, it is likely that our model underestimated the
ﬁnancial impact of medical errors. Further national studies on
the subject are required [29].
Sales of dopamine in Colombia, according to ofﬁcial data,
accounted for 17,555 vials in a 12-month period (2011–2012). If our
assumptions are correct, the Colombian health system could save
up to COP $1.1 billion (around half a million US dollars) if
premixed dopamine were used.
Of the four drug delivery systems, the one showing higher
cost variability is the compounding center drug preparation, for
two reasons: the ﬁrst one is economies of scale. A large mixing
center can expect lower marginal costs, thereby having signiﬁ-
cant differences compared with the ﬁnal costs of a small com-
pounding center. The other one is opportunity cost; oncologicaldministration in the ICU, with wide intervals used for
ase case Low High Source
0.08 0.04 0.12 [14]
0.03 0.005 0.05 [14]
0.01 0.005 0.05 [15]
0.0027 0.001 0.05 [15]
0.063 0.010 0.300 [10]
0.014 0.001 0.050 [6]
0.004 0.001 0.020 [6]
Fig. 2 – Tornado diagram showing variables with the greatest effect on the results. Dark bar shows critical variables, those that
can change the least costly alternative between compounding center and premix. The x-axis represents the change in mean
cost. ICU, intensive care unit.
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larger proﬁt margin because they have a higher wholesale price
(and proﬁt is generally a relatively constant proportion of this
price).
The main lesson learned is that medication administration
errors, particularly in the ICU, can be both more common and
more costly than generally assumed. Efforts to prevent them
should not only consider quality and safety issues but could also
be intended to reduce costs.Conclusions
The use of premix drugs at the ICU setting, as part of a strategy
aimed at reducing errors, might improve the quality of health
care, reducing adverse events attributable to drug administration
and reducing costs for the health system.Source of ﬁnancial support: This study was ﬁnancially sup-
ported by Baxter Laboratories S.A.
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